HLX04 vs IBI305

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

HLX04 · Hanbeitai

Marketed by Shanghai Henlius Biotech

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03952403 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.

Reported efficacy

Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. (mixed)

Result source: NCT03952403

IBI305

Marketed by Innovent Biologics

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT02954172 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.

Reported efficacy

Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)

Result source: NCT02954172

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHLX04IBI305
PFS, median—Not reported8.4 vs 8.3vs Bevacizumabn 221NCT02954172
OS, median—Not reported18.0n 221NCT02954172
ORR—Not reported44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172
Duration of response, median—Not reported—Not reported

PFS, median

HLX04
—Not reported
IBI305
8.4 vs 8.3vs Bevacizumabn 221NCT02954172

OS, median

HLX04
—Not reported
IBI305
18.0n 221NCT02954172

ORR

HLX04
—Not reported
IBI305
44.3% vs 46.4%vs Bevacizumabwk 18 · n 221NCT02954172

Duration of response, median

HLX04
—Not reported
IBI305
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HLX04
ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. NCT03952403 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HLX04: 0 of 4 rows · IBI305: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIBI305
Dropout rate
1.3%a
NCT02954172 · Phase 3 · combination
Discontinued due to AEs
—a
NCT02954172 · Phase 3 · combination
Serious AEs
33.5%a
NCT02954172 · Phase 3 · combination
Most frequent reported AEs
a
white blood cell count decreased 71.9%
neutrophil count decreased 70.5%
platelet count decreased 50.4%
NCT02954172 · Phase 3 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

IBI305

ORR 44.3% (n=221) vs 46.4% (n=220) Bevacizumab @ 18wk
responder rate · % of participants
NCT02954172 · Phase 3 · combination
Overall Survival 18.02 vs NA Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination
PFS 8.43 vs 8.26 Bevacizumab months
time to event · months
NCT02954172 · Phase 3 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX04's landscape · IBI305's landscape